echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ASM Biotech declares the third domestic CD20/CD3 double antibody

    ASM Biotech declares the third domestic CD20/CD3 double antibody

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text | Pick up Bay

    On April 27, the CDE official website showed that the clinical trial application for the EX103 injection of the CD20/CD3 bispecific antibody from Esmilion was accepted by the NMPA.


    EX103 is developed using ExMab, a four-chain bispecific antibody platform from Esmin Biotech.


    The EX103 of ASM Biologics is the fourth CD20/CD3 bispecific antibody to be declared clinically in China.


    Roche developed a new type of "2:1" double antibody against glofitamab, which contains 2 Fabs that bind CD20 and 1 Fab that binds CD3.


    mosunetuzumab is another CD3/CD20 double antibody developed by Luo.


    REGN1979 was developed by Regeneron.


    REGN1979

    Domestic companies, Nuocheng Jianhua, Jiahe Biological, and Bojin Biological have also deployed CD20/CD3 dual antibodies, which are currently in the preclinical development stage.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.